Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.33)
# 386
Out of 5,182 analysts
96
Total ratings
55.07%
Success rate
18.14%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVMD Revolution Medicines | Maintains: Outperform | $140 → $200 | $131.67 | +51.89% | 1 | Apr 14, 2026 | |
| UPB Upstream Bio | Downgrades: In-Line | $40 → $15 | $9.29 | +61.46% | 2 | Mar 27, 2026 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $30 → $45 | $30.64 | +46.87% | 3 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $100 → $125 | $74.52 | +67.74% | 4 | Feb 25, 2026 | |
| ACLX Arcellx | Downgrades: In-Line | $115 | $115.07 | -0.06% | 2 | Feb 24, 2026 | |
| VIR Vir Biotechnology | Maintains: Outperform | $12 → $18 | $10.64 | +69.17% | 2 | Feb 24, 2026 | |
| MRNA Moderna | Maintains: In-Line | $28 → $35 | $48.70 | -28.13% | 7 | Feb 17, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $744.44 | +17.54% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $23.49 | +70.29% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $18.59 | +195.86% | 1 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $29.17 | +20.01% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $10.19 | +145.34% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $80 | $61.60 | +29.87% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $22.12 | +53.71% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $54.26 | +1.36% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $128.04 | +44.49% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $102.06 | +22.48% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $53.81 | +95.15% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $23.99 | +266.82% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $180.67 | +52.76% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.26 | +973.62% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $340.18 | -31.80% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $95.72 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $127.75 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $33.73 | -37.74% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $7.51 | +206.26% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.69 | +491.72% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $17.65 | - | 5 | Feb 14, 2018 |
Revolution Medicines
Apr 14, 2026
Maintains: Outperform
Price Target: $140 → $200
Current: $131.67
Upside: +51.89%
Upstream Bio
Mar 27, 2026
Downgrades: In-Line
Price Target: $40 → $15
Current: $9.29
Upside: +61.46%
Edgewise Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $30 → $45
Current: $30.64
Upside: +46.87%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $100 → $125
Current: $74.52
Upside: +67.74%
Arcellx
Feb 24, 2026
Downgrades: In-Line
Price Target: $115
Current: $115.07
Upside: -0.06%
Vir Biotechnology
Feb 24, 2026
Maintains: Outperform
Price Target: $12 → $18
Current: $10.64
Upside: +69.17%
Moderna
Feb 17, 2026
Maintains: In-Line
Price Target: $28 → $35
Current: $48.70
Upside: -28.13%
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $744.44
Upside: +17.54%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $23.49
Upside: +70.29%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $18.59
Upside: +195.86%
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $29.17
Upside: +20.01%
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $10.19
Upside: +145.34%
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $61.60
Upside: +29.87%
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $22.12
Upside: +53.71%
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $54.26
Upside: +1.36%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $128.04
Upside: +44.49%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $102.06
Upside: +22.48%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $53.81
Upside: +95.15%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $23.99
Upside: +266.82%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $180.67
Upside: +52.76%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.26
Upside: +973.62%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $340.18
Upside: -31.80%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $95.72
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $127.75
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $33.73
Upside: -37.74%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $7.51
Upside: +206.26%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.69
Upside: +491.72%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $17.65
Upside: -